2-Benzazepin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-Benzazepin-2-amine
• 英文别名: 2-benzazepin-2-amine
• 化学式: C₁₀H₁₀N₂
• 分子量: 158.2
• InChiKey: CUJJWOUYYROEOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP2976086A1

  公开（公告）日：2016-01-27
• BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3317427A1

  公开（公告）日：2018-05-09
• [EN] COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE<br/>[FR] COMBINAISON D'INHIBITEURS CATALYTIQUES DE MTORC1/2 ET INHIBITEURS SÉLECTIFS DE LA KINASE AURORA A
  申请人：MILLENNIUM PHARM INC

  公开号：WO2014153509A1

  公开（公告）日：2014-09-25

  Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is MLN8237.
• [EN] BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE<br/>[FR] BIOMARQUEURS DE RÉPONSE À DES INHIBITEURS SÉLECTIFS D'AURORA A KINASE
  申请人：MILLENNIUM PHARM INC

  公开号：WO2017003845A1

  公开（公告）日：2017-01-05

  Disclosed herein are WNT and Hippo pathway markers associated with sensitivity to treatment with Aurora A kinase inhibitors. Claimed genes include LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XP01, ROR2, CCND1 & CTNNB1 (WNT pathway) and AMOT, DVL2, LATS1, LATS2, MOB1 B, NPHP4, TJP1, TJP2, WCC1, WWTR1 & YAP1 (Hippo pathway). Sensitivity to treatment with an Aurora A kinase inhibitor is observed when the aforementioned markers have mutations in tumor cells. Compositions and methods are provided to assess marker genes to predict response to Aurora Kinase A inhibition treatment and for patient selection.